Latest News about BMY
Recent news which mentions BMY
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
November 22, 2022
From Motley Fool
Southwest Gas, Albemarle, Bristol-Myers Squibb And This Fintech Play On CNBC's 'Final Trades'
November 22, 2022
From Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
From Benzinga
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
November 18, 2022
Tickers
BMY
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
From Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
November 18, 2022
Tickers
BMY
From Benzinga
2 Stocks to Buy Whether or Not a Recession Is Coming
November 18, 2022
From Motley Fool
OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer
November 16, 2022
From Benzinga
From Benzinga
Why Are Healthcare Stocks Down Today?
November 11, 2022
From InvestorPlace
Is This Blue-Chip Dividend Stock a Buy?
November 11, 2022
From Motley Fool
SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients
November 10, 2022
From Benzinga
Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies
November 10, 2022
From Benzinga
2 Ultra-Safe Passive Income Stocks to Buy Right Now
November 10, 2022
From Motley Fool
Buy Bristol-Myers Squibb, Merck, 10-Year Treasury ETF And This Payments Stock: CNBC's 'Final Trades'
November 10, 2022
From Benzinga
Here's Why This Growth Stock Is Already My 2022 Winner
November 09, 2022
From Motley Fool
The 7 Best Pharma Stocks to Buy Now
November 08, 2022
From InvestorPlace
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
November 08, 2022
From Motley Fool
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
November 07, 2022
From Benzinga
A $10,000 Investment at the Start of the Great Recession Would Be Worth This Much Today
November 04, 2022
From Motley Fool
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
October 31, 2022
From Benzinga
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
October 27, 2022
From Benzinga
From Benzinga
If You Invested $10,000 in Bristol Myers Squibb 5 Years Ago, This Is How Much You Would Have Today
October 27, 2022
Tickers
BMY
From Motley Fool
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
October 27, 2022
From Benzinga
Tickers
BMY
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.